Market Overview

Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021

Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021

Regeneron Pharmaceuticals Inc (NASDAQ: REGNsaid Wednesday that it requested emergency use authorization from the FDA for its investigational coronavirus antibody cocktail.

The experimental drug, named REGN-COV2, was in news last week after it was administered to President Donald Trump. 

What Is REGN-COV2? REGN-COV2 is a combination of two monoclonal antibodies: REGN10933 and REGN10987.

The company said it  has doses 50,000 patients and hopes to make available doses for 300,000 patients in the months ahead. 

Regeneron's early data — and perhaps the Trump news — have led to the FDA being supportive of the company filing, Cantor Fitzgerald analyst Alethia Young said in a Thursday note. 

Patient Access In Q4? The filing means that patients could obtain access to the drug in the fourth quarter, Young said.

The analyst's base case assumes COVID-19 sales of $1.8 billion in 2021 for Regeneron, with a 50% probability of success.

Assuming 100% success on Cantor's revenue forecasts for 2021-2023, $18 per share would be added to Regeneron's valuation, she said. 

Going by the urgency with which Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir was approved, REGN-COV2 could be approved in the coming weeks — especially as COVID-19 remains an urgent issue in the U.S., Young said. 

"Our positive thesis on REGN is more than REGN-COV2, but certainly we think commercial sales from REGN-COV2 could be a near-term positive earnings driver for 2021." 

Dupixent is likely to be another earnings growth driver for Regeneron, the analyst said. 

Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Regeneron Vs. Lilly: The coronavirus antibodies from Regeneron and Eli Lilly And Co (NYSE: LLY), which submitted an emergency use application Wednesday, have similar efficacy and safety, Canaccord Genuity analyst John Newman said in a note. 

The lack of baseline viral load data for Lilly is not helpful, the analyst said. 

Regeneron's antibody cocktail showed better efficacy for higher viral loads or in patients who were likely more ill, while Lilly did not disclose any such data, he said.

Hospitalization or medical visits for both were similar, with Lilly holding a slight edge, Newman said. 

"Importantly, Regeneron illustrated faster symptom resolutions in patients with higher viral load at baseline."

Cantor Fitzgerald has an Overweight rating on Regeneron with a $690 price target. 

Canaccord Genuity maintained a Buy rating and $700 price target.

REGN Price Action: At last check, Regeneron shares were rising 2.14% to $604.34. 

Latest Ratings for REGN

Oct 2020Morgan StanleyMaintainsEqual-Weight
Oct 2020SVB LeerinkMaintainsOutperform
Oct 2020Cantor FitzgeraldUpgradesNeutralOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration FDA Top Stories Best of Benzinga

Latest Ratings

INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at